Themed "Global IVD Innovation & Cross-Regional Integration," this groundbreaking event brings together distinguished experts from around the world to explore the future of diagnostics.

On November 15, 2021, Vazyme Biotech Co., Ltd. (hereinafter referred to as "Vazyme") was listed on SSE STAR Market. Stock abbreviation: Vazyme, stock code: 688105. The issue price is 55 yuan/share, and the opening price is 74 yuan/share.

The US Food and Drug Administration on Monday released revised guidance on its regulatory priorities and policies for COVID-19 tests.

Siemens Healthineers (ETR:SHL) shares ticked up today on fourth-quarter results that topped the consensus sales forecast.

An artificial intelligence (AI)-based technology rapidly diagnoses rare disorders in critically ill children with high accuracy, according to a report by researchers from University of Utah (U Of U) Health, Fabric Genomics, and collaborators on a study led by Rady Children’s Hospital in San Diego.

DiaSorin said in Q3 it saw a strong recovery of non-COVID test sales including for latent tuberculosis and other infectious diseases as well as gastrointestinal infections.

On November 10, Wuhan Landing Med officially announced that it had completed the round-D financing of RMB 320 million, which was led by Ali Health and followed by Ether Capital.

The funding will be used to provide purchase commitments to manufacturers so they can scale up test production.

Meridian Bioscience announced on Wednesday that its Revogene SARS-CoV-2 test has received Emergency Use Authorization from the US Food and Drug Administration.

Britain said it would recognise COVID-19 vaccines on the World Health Organization's Emergency Use Listing later this month.

Viome Life Sciences said Wednesday that it has raised $54M in pre-series C convertible funding with participation from existing and new investors. Added to prior funding, including a series B round in November 2019, the company said it has raised over $125M in total.